Mostrar registro simples

dc.contributor.authorGiongo, Franciele Kichpt_BR
dc.contributor.authorLopes, Matheus Gallaspt_BR
dc.contributor.authorBenvenutti, Radharanipt_BR
dc.contributor.authorSachett, Adrielipt_BR
dc.contributor.authorBastos, Leonardo Marensipt_BR
dc.contributor.authorRosa, Adriane Ribeiropt_BR
dc.contributor.authorHerrmann, Ana Paulapt_BR
dc.date.accessioned2024-11-27T06:54:00Zpt_BR
dc.date.issued2023pt_BR
dc.identifier.issn1469-5111pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/281630pt_BR
dc.description.abstractBackground: Altered redox state and developmental abnormalities in glutamatergic and GABAergic transmission during development are linked to the behavioral changes associated with schizophrenia. As an amino acid that exerts antioxidant and inhibitory actions in the brain, taurine is a potential candidate to modulate biological targets relevant to this disorder. Here, we investigated in mice and zebrafish assays whether taurine prevents the behavioral changes induced by acute administration of MK-801 (dizocilpine), a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist. Methods: C57BL/6 mice were i.p. administered with saline or taurine (50, 100, and 200 mg/kg) followed by MK-801 (0.15 mg/ kg). Locomotor activity, social interaction, and prepulse inhibition of the acoustic startle reflex were then assessed in different sets of animals. Zebrafish were exposed to tank water or taurine (42, 150, and 400 mg/L) followed by MK-801 (5 µM); social preference and locomotor activity were evaluated in the same test. Results: MK-801 induced hyperlocomotion and disrupted sensorimotor gating in mice; in zebrafish, it reduced sociability and increased locomotion. Taurine was mostly devoid of effects and did not counteract NMDA antagonism in mice or zebrafish. Discussion: Contradicting previous clinical and preclinical data, taurine did not show antipsychotic-like effects in the present study. However, it still warrants consideration as a preventive intervention in animal models relevant to the prodromal phase of schizophrenia; further studies are thus necessary to evaluate whether and how taurine might benefit patients.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofThe international journal of neuropsychopharmacology. Cambridge. Vol. 26, no. 2 (Feb. 2023), p. 125-136pt_BR
dc.rightsOpen Accessen
dc.subjectEsquizofreniapt_BR
dc.subjectBehavioren
dc.subjectComportamentopt_BR
dc.subjectC57BL/6en
dc.subjectMK-801en
dc.subjectTaurinapt_BR
dc.subjectSchizophreniaen
dc.subjectPeixe-zebrapt_BR
dc.subjectTaurineen
dc.subjectZebrafishen
dc.titleEffects of taurine in mice and zebrafish behavioral assays with translational relevance to schizophreniapt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001211068pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples